31052-93-4

Upstream product

• 1428747-17-4 (2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)carbamic acid tert-butylester 
• 86843-98-3 6-bromo-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine 
• 100-47-0 benzonitrile 
• 1072-97-5 5-bromo-2-pyridylamine 

Downstream Products

• 1428746-98-8 6-cyclopropyl-3-methoxy-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazine-2-carboxamide 
• 1428746-69-3 1-methyl-5-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-6-ylcarbamoyl)-1H-pyrazole-4-carboxylic acid 
• 1428746-70-6 2-methyl-4-(pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-amide 
• 1428747-20-9 1-methyl-5-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-6-ylcarbamoyl)-1H-pyrazole-4-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

FUSED RING COMPOUND HAVING UREA STRUCTURE

The present invention relates to a novel fused ring compound having urea structure that exhibits excellent NAMPT activating effect, and a method using the same for treating / preventing metabolic disorder, cardiovascular and kidney disease, mitochondrial disease, neurodegenerative disease, ocular disease, and muscle wasting disorder. The present invention provides a compound represented by following formula (I) or a pharmacologically acceptable salt: Formula (I) wherein A, B, R, R2 and R3 represent the same meanings as in the claims.

TRIAZOLOPYRIDINE COMPOUNDS AS PDE10A INHIBITORS

The invention is concerned with triazolopyridine compounds of formula (I) wherein R1, R2 and R3 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhi